ReviewFrontiers in cell and developmental biology2025
Metabolic state and female fertility in ART cycles: a summary of current advances.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Addressing multiple pregnancies in in vitro fertilization-embryo transfer: Current status, challenges, and solutions.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Review
- Pregnancy as a Window for Hypertension and Cardiovascular Prevention in Women: A Life-Course Perspective Based on the 2025 ESC Guidelines.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This mini review explores the evolving landscape of metabolic disturbances and their impact on female reproductive outcomes, with a particular focus on emerging molecular biomarkers and novel metabolic phenotypes. Metabolic health plays a pivotal role in female reproductive function, with well-established endocrine-metabolic disorders, such as polycystic ovary syndrome, obesity, and diabetes mellitus, known to impair fertility. This review explores these conditions, including less commonly studied phenotypes like normal weight obesity, metabolically obese normal weight, and metabolically healthy obesity, which challenge traditional diagnostic frameworks by presenting metabolic risk independent of body mass index. These underrecognized profiles can adversely affect ovarian physiology, endometrial receptivity, and assisted reproductive technology outcomes. The review further highlights potential biomarkers, including bile acids and advanced glycation end-products, as promising diagnostic and therapeutic targets. By integrating insights from metabolic regulation, endocrinology, and reproductive biology, this article emphasizes the need for a more nuanced, individualized approach to fertility assessment and treatment. Understanding these interconnections is vital for advancing personalized medicine, particularly in addressing unexplained infertility and optimizing assisted reproductive technology success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.